{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:31:54Z","timestamp":1769074314040,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018726","name":"Epilepsy Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.yebeh.2022.108868","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T18:28:24Z","timestamp":1660674504000},"page":"108868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center"],"prefix":"10.1016","volume":"135","author":[{"given":"Sebastian F.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Hare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehreen","family":"Kassam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergus","family":"Rugg-Gunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias J.","family":"Koepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josemir W.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Rajakulendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108868_b0005","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.yebeh.2007.11.013","article-title":"Quality-of-life trajectories in epilepsy: A review of the literature","volume":"12","author":"Jacoby","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0015","doi-asserted-by":"crossref","unstructured":"Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, et al. B. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia 2016;57:538-48.","DOI":"10.1111\/epi.13340"},{"key":"10.1016\/j.yebeh.2022.108868_b0020","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1111\/epi.14532","article-title":"Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein","volume":"59","author":"Wood","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0025","first-page":"5719","article-title":"Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures","volume":"9","author":"Mumoli","year":"2015","journal-title":"Drug Design Dev Ther"},{"key":"10.1016\/j.yebeh.2022.108868_b0030","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0045","doi-asserted-by":"crossref","first-page":"106864","DOI":"10.1016\/j.yebeh.2019.106864","article-title":"Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis","volume":"103","author":"Brandt","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0055","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1528-1157.1999.tb02017.x","article-title":"The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy","volume":"40","author":"Wong","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0060","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/j.1528-1157.2000.tb00165.x","article-title":"Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy","volume":"41","author":"Lhatoo","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.yebeh.2006.12.005","article-title":"Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability","volume":"10","author":"Simister","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eplepsyres.2009.08.001","article-title":"The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre","volume":"87","author":"Yuen","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108868_b0075","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.seizure.2014.08.001","article-title":"Long term retention of retigabine in a cohort of people with drug resistant epilepsy","volume":"23","author":"Wehner","year":"2014","journal-title":"Seizure-Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108868_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","article-title":"Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey","volume":"48","author":"Steinhoff","year":"2017","journal-title":"Seizure-Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108868_b0085","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.seizure.2018.07.017","article-title":"Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis","volume":"61","author":"Hirsch","year":"2018","journal-title":"Seizure-Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108868_b0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2018.00038","article-title":"Brivaracetam in the Treatment of Patients with epilepsy-First clinical experiences","volume":"9","author":"Zahnert","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2022.108868_b0100","doi-asserted-by":"crossref","first-page":"106329","DOI":"10.1016\/j.eplepsyres.2020.106329","article-title":"Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe","volume":"165","author":"Steinhoff","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108868_b0105","doi-asserted-by":"crossref","first-page":"106967","DOI":"10.1016\/j.yebeh.2020.106967","article-title":"Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation","volume":"106","author":"Adewusi","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0110","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108868_b0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eplepsyres.2017.02.007","article-title":"Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study","volume":"131","author":"Asadi-Pooya","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108868_b0120","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/epi.16769","article-title":"Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis","volume":"62","author":"Lattanzi","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108868_b0125","doi-asserted-by":"crossref","first-page":"107897","DOI":"10.1016\/j.yebeh.2021.107897","article-title":"Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial","volume":"118","author":"Toledo","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0130","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","article-title":"Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: A single centre evaluation","volume":"106","author":"Novy","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108868_b0135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yebeh.2017.04.006","article-title":"Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center","volume":"73","author":"Wehner","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0140","first-page":"24","article-title":"Long-term retention and efficacy of levetiracetam in a large cohort of patients with chronic epilepsy","volume":"12","author":"Depondt","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2022.108868_b0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Pharmacokinetics"},{"issue":"12","key":"10.1016\/j.yebeh.2022.108868_b0150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2022.108868_b0155","doi-asserted-by":"crossref","first-page":"106236","DOI":"10.1016\/j.eplepsyres.2019.106236","article-title":"Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? \u2013 A case series","volume":"159","author":"Steinhoff","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108868_b0160","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108868_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108868_b0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2019.04.021","article-title":"Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study","volume":"69","author":"Toledo","year":"2019","journal-title":"Seizure Eur J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108868_b0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.seizure.2022.02.007","article-title":"Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: A retrospective outcome analysis","volume":"96","author":"Snoeren","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108868_b0185","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.1111\/epi.13890","article-title":"Brivaracetam does not modulate ionotropic channels activated by glutamate, gamma-aminobutyric acid, and glycine in hippocampal neurons","volume":"58","author":"Niespodziany","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108868_b0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0891-4222(00)00061-5","article-title":"The prevalence of challenging behaviors: a total population study","volume":"22","author":"Emerson","year":"2001","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.yebeh.2022.108868_b0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.seizure.2020.07.018","article-title":"Epilepsy, antiseizure medication, intellectual disability and challenging behaviour - Everyone's business, no one's priority","volume":"81","author":"Kinney","year":"2020","journal-title":"Seizure Eur J Epilepsy"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022003171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022003171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:47:22Z","timestamp":1761504442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022003171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"alternative-id":["S1525505022003171"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108868","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108868"}}